CLINICAL TRIALS PROFILE FOR KADIAN

All Clinical Trials for Kadian

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00415597 ↗	Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain	Completed	Pfizer	Phase 3	2006-12-01	Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months.
NCT00420992 ↗	A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee	Completed	Pfizer	Phase 3	2006-12-01	The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with placebo for treating moderate to severe chronic pain over a 12 week period.
NCT00759356 ↗	Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions	Completed	Actavis Inc.	Phase 1	2004-08-01	The objective of this single-dose, open-label, randomized, two-period crossover study was to compare the rate of absorption and oral bioavailability of a test formulation of morphine sulfate 200 mg sustained-release capsules manufactured by Alpharma Branded Products Division Inc. to an equivalent oral dose of the commercially available reference product, KADIAN 2 x 100 mg capsules manufactured by Alpharma Branded Products Division Inc. when administered under fed conditions.
NCT00759759 ↗	Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fasting Conditions	Completed	Actavis Inc.	Phase 1	2004-09-01	The objective of this single-dose, open-label, randomized, two-period crossover study was to compare the rate of absorption and oral bioavailability of a test formulation of morphine sulfate 200 mg sustained-release capsules manufactured by Alpharma Branded Products Division Inc. to an equivalent oral dose of the commercially available reference product, KADIAN 2 x 100 mg capsules manufactured by Alpharma Branded Products Division Inc. when administered after a 10-hour overnight fast.
NCT00759902 ↗	Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions	Completed	Actavis Inc.	Phase 1	2006-08-01	The objective of this single-dose, open-label, randomized, two-treatment, two-period crossover study was to compare the relative bioavailability of a test formulation of KADIAN (2 x 10 mg) capsules manufactured by Alpharma Inc. to an equivalent oral dose of the commercially available reference product, KADIAN (1 x 20 mg)capsules manufactured by Alpharma Branded Products Inc. following an overnight fast of at least 10 hours.

Clinical Trial Conditions for Kadian

Condition Name

Condition Name for Kadian
Intervention	Trials
Healthy	6
Pain	3
Methadone	1
Fentanyl	1

Condition MeSH

Condition MeSH for Kadian
Intervention	Trials
Disease	4
Acute Pain	2
Opioid-Related Disorders	2
Neoplasms, Second Primary	1

Clinical Trial Locations for Kadian

Trials by Country

Trials by Country for Kadian
Location	Trials
United States	66
Canada	2

Trials by US State

Trials by US State for Kadian
Location	Trials
Texas	10
California	3
Arizona	3
Missouri	2
Michigan	2

Clinical Trial Progress for Kadian

Clinical Trial Phase

Clinical Trial Phase for Kadian
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	4
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Kadian
Clinical Trial Phase	Trials
Completed	10
Suspended	2
Not yet recruiting	2

Clinical Trial Sponsors for Kadian

Sponsor Name

Sponsor Name for Kadian
Sponsor	Trials
Actavis Inc.	6
Pfizer	2
University Health Network, Toronto	1

Sponsor Type

Sponsor Type for Kadian
Sponsor	Trials
Industry	11
Other	10
U.S. Fed	2